Actively Recruiting
Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)
Led by University Hospital, Bordeaux · Updated on 2025-03-19
80
Participants Needed
3
Research Sites
101 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Myelodysplastic syndromes (MDS) are clonal diseases of hematopoietic stem cells (HSC) characterized by dysplastic and inefficient hematopoiesis related to excessive progenitor cell death. Ferroptosis is a recently described cell death mechanism and we think that it could be a major player in the pathophysiology of MDS, involved in the cell death that characterizes these diseases and contributing to cytopenias. The study aims to demonstrate that there is a significant activation of this phenomenon in MDS patients compared to a population of subjects without MDS.
CONDITIONS
Official Title
Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older
- Affiliated to or benefiting from a social security scheme
- Signed free, written, and informed consent
- For MDS patients: sampling at diagnosis according to WHO 2016 criteria
- Presence of ring sideroblasts on bone marrow smear for MDS patients
- For MGUS patients: sampling as part of MGUS exploration according to WHO 2016 criteria
You will not qualify if you...
- Red blood cell transfusion within 120 days before sample collection
- Treatment with hematopoietic growth factors (EPO, TPO, G-CSF) within 30 days before collection
- Conditions affecting systemic iron metabolism such as hemochromatosis, Gaucher disease, ferroportin disease, or porphyria cutanea tarda
- Under legal protection measures (guardianship, curatorship)
- Deprived of liberty by judicial or administrative decision
- Unable to give consent
- In exclusion period after another study or participated in another interventional drug study within 30 days before entry
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
CHU de Bordeaux, Laboratoire d'Hématologie
Pessac, France
Not Yet Recruiting
2
CHU de Bordeaux, Service de Médecine Interne
Pessac, France
Not Yet Recruiting
3
CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire
Pessac, France
Actively Recruiting
Research Team
V
Victor-Emmanuel BRETT
CONTACT
C
Charles DUSSIAU
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here